Substance / Medication

Amphotericin B lipid complex

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Cryptococcal meningitis

Coccidioidomycosis

Aspergillosis

Candidiasis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis.

Safdar Amar, Ma Jonathan, Saliba Fouzi et al. · Medicine (Baltimore) · 2010

PMID: 20616663Meta-Analysis

Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature.

Martino Rodrigo · Curr Med Res Opin · 2004

PMID: 15119986Meta-Analysis

Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients.

Husain Shahid, Capitano Blair, Corcoran Timothy et al. · Transplantation · 2010

PMID: 20881664RCT

Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.

Alexander B D, Dodds Ashley E S, Addison R M et al. · Transpl Infect Dis · 2006

PMID: 16623816Trial

Population pharmacokinetics of amphotericin B lipid complex in neonates.

Würthwein Gudrun, Groll Andreas H, Hempel Georg et al. · Antimicrob Agents Chemother · 2005

PMID: 16304177TrialFull text (PMC)

Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies.

Martino Rodrigo, Cortés Montserrat, Subirá Maricel et al. · Leuk Lymphoma · 2005

PMID: 16194888Trial

Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.

Mattiuzzi Gloria N, Kantarjian Hagop, Faderl Stefan et al. · Cancer · 2004

PMID: 14745876Trial

Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.

López-Vélez Rogelio, Videla Sebastián, Márquez Manuel et al. · J Antimicrob Chemother · 2004

PMID: 14739148Trial

Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients.

Drew Richard H, Dodds Ashley Elizabeth, Benjamin Daniel K et al. · Transplantation · 2004

PMID: 14742987Trial

Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.

Subirà Maricel, Martino Rodrigo, Gómez Lucia et al. · Eur J Haematol · 2004

PMID: 15059069Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Amphotericin B lipid complex (substance)
SNOMED CT: 425953004
UMLS CUI: C4521099

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.